PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter sold 1,034 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $79,049.30. Following the completion of the transaction, the chief accounting officer directly owned 72,693 shares of the company’s stock, valued at approximately $5,557,379.85. The trade was a 1.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Christine Marie Utter also recently made the following trade(s):

• On Wednesday, January 7th, Christine Marie Utter sold 1,235 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.45, for a total transaction of $95,650.75.
• On Tuesday, January 6th, Christine Marie Utter sold 1,381 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $106,267.95.

PTC Therapeutics Stock Up 0.1%

PTC Therapeutics stock traded up $0.06 during trading hours on Monday, hitting $77.59. 2,631,928 shares of the company traded hands, compared to its average volume of 1,795,906. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The firm has a market cap of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49. The firm’s 50-day simple moving average is $76.61 and its two-hundred day simple moving average is $62.91.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same period last year, the firm posted ($1.39) earnings per share. The business’s revenue was up 7.2% on a year-over-year basis. On average, equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PTCT. Jefferies Financial Group Inc. acquired a new stake in PTC Therapeutics during the 3rd quarter valued at $97,252,000. SG Americas Securities LLC grew its holdings in shares of PTC Therapeutics by 587.5% during the fourth quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock valued at $67,943,000 after buying an additional 764,364 shares in the last quarter. Hood River Capital Management LLC grew its holdings in shares of PTC Therapeutics by 654.4% during the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after buying an additional 552,130 shares in the last quarter. State Street Corp raised its position in PTC Therapeutics by 22.1% during the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after buying an additional 541,558 shares during the period. Finally, Palo Alto Investors LP lifted its stake in PTC Therapeutics by 112.2% in the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after acquiring an additional 456,144 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 target price on shares of PTC Therapeutics in a research note on Thursday. Wells Fargo & Company raised their price objective on shares of PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. TD Cowen increased their target price on shares of PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $77.27.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.